Review treatment and prescribing with the chosen scope
Connecticut 19a-906 restricts telehealth prescribing of Schedule I, II, and III substances, with specified exceptions for certain Schedule II or III uses. The provision also requires consistency with the referenced federal law and electronic submission for those prescriptions. Connecticut controlled-prescribing provision
Have qualified advisers review the exact professional, medicine, and clinical use. Do not reduce the law to either universal online prescribing or a universal ban. A narrow launch may exclude controlled medicines until the relevant pathway is fully reviewed.
For controlled medications, the DEA and HHS fourth temporary extension of telemedicine prescribing flexibilities runs through December 31, 2026, subject to its conditions. It does not guarantee a prescription or replace state requirements, and any reliance on it beyond that date needs a fresh review. State restrictions continue to matter. Federal temporary controlled-prescribing extension
Ensure the patient-facing explanation reflects the clinician's decision process. Translated advertisements should not promise a medicine that the English version carefully qualifies. Review both versions together. Include a clear explanation of what happens when the professional recommends additional assessment or declines the requested treatment.